These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 30392411)

  • 1. Schizophrenia Polygenic Risk Score as a Predictor of Antipsychotic Efficacy in First-Episode Psychosis.
    Zhang JP; Robinson D; Yu J; Gallego J; Fleischhacker WW; Kahn RS; Crespo-Facorro B; Vazquez-Bourgon J; Kane JM; Malhotra AK; Lencz T
    Am J Psychiatry; 2019 Jan; 176(1):21-28. PubMed ID: 30392411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort.
    Santoro ML; Ota V; de Jong S; Noto C; Spindola LM; Talarico F; Gouvea E; Lee SH; Moretti P; Curtis C; Patel H; Newhouse S; Carvalho CM; Gadelha A; Cordeiro Q; Bressan RA; Belangero SI; Breen G
    Transl Psychiatry; 2018 Aug; 8(1):174. PubMed ID: 30171181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia.
    Lin BD; Pinzón-Espinosa J; Blouzard E; van der Horst MZ; Okhuijsen-Pfeifer C; van Eijk KR; Guloksuz S; Peyrot WJ; Luykx JJ;
    JAMA Psychiatry; 2023 Feb; 80(2):181-185. PubMed ID: 36542388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Examination of Polygenic Score Risk Prediction in Individuals With First-Episode Psychosis.
    Vassos E; Di Forti M; Coleman J; Iyegbe C; Prata D; Euesden J; O'Reilly P; Curtis C; Kolliakou A; Patel H; Newhouse S; Traylor M; Ajnakina O; Mondelli V; Marques TR; Gardner-Sood P; Aitchison KJ; Powell J; Atakan Z; Greenwood KE; Smith S; Ismail K; Pariante C; Gaughran F; Dazzan P; Markus HS; David AS; Lewis CM; Murray RM; Breen G
    Biol Psychiatry; 2017 Mar; 81(6):470-477. PubMed ID: 27765268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis.
    Sengupta SM; MacDonald K; Fathalli F; Yim A; Lepage M; Iyer S; Malla A; Joober R
    Schizophr Res; 2017 Jun; 184():116-121. PubMed ID: 27916287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Schizophrenia-Related Polygenic Liability and the Occurrence and Level of Mood-Incongruent Psychotic Symptoms in Bipolar Disorder.
    Allardyce J; Leonenko G; Hamshere M; Pardiñas AF; Forty L; Knott S; Gordon-Smith K; Porteous DJ; Haywood C; Di Florio A; Jones L; McIntosh AM; Owen MJ; Holmans P; Walters JTR; Craddock N; Jones I; O'Donovan MC; Escott-Price V
    JAMA Psychiatry; 2018 Jan; 75(1):28-35. PubMed ID: 29167880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study.
    Rodriguez V; Alameda L; Quattrone D; Tripoli G; Gayer-Anderson C; Spinazzola E; Trotta G; Jongsma HE; Stilo S; La Cascia C; Ferraro L; La Barbera D; Lasalvia A; Tosato S; Tarricone I; Bonora E; Jamain S; Selten JP; Velthorst E; de Haan L; Llorca PM; Arrojo M; Bobes J; Bernardo M; Arango C; Kirkbride J; Jones PB; Rutten BP; Richards A; Sham PC; O'Donovan M; Van Os J; Morgan C; Di Forti M; Murray RM; Vassos E
    Psychol Med; 2023 Jun; 53(8):3396-3405. PubMed ID: 35076361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
    Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
    J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polygenic risk score prediction of antipsychotic dosage in schizophrenia.
    Hettige NC; Cole CB; Khalid S; De Luca V
    Schizophr Res; 2016 Feb; 170(2-3):265-70. PubMed ID: 26778674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interplay between Schizophrenia Polygenic Risk Score and Childhood Adversity in First-Presentation Psychotic Disorder: A Pilot Study.
    Trotta A; Iyegbe C; Di Forti M; Sham PC; Campbell DD; Cherny SS; Mondelli V; Aitchison KJ; Murray RM; Vassos E; Fisher HL
    PLoS One; 2016; 11(9):e0163319. PubMed ID: 27648571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
    Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
    J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schizophrenia polygenic risk score and 20-year course of illness in psychotic disorders.
    Jonas KG; Lencz T; Li K; Malhotra AK; Perlman G; Fochtmann LJ; Bromet EJ; Kotov R
    Transl Psychiatry; 2019 Nov; 9(1):300. PubMed ID: 31727878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical profiles, scope and general findings of the Western Sydney First Episode Psychosis Project.
    Harris A; Brennan J; Anderson J; Taylor A; Sanbrook M; Fitzgerald D; Lucas S; Redoblado-Hodge A; Gomes L; Gordon E
    Aust N Z J Psychiatry; 2005; 39(1-2):36-43. PubMed ID: 15660704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trajectories of symptom dimensions in short-term response to antipsychotic treatment in patients with a first episode of non-affective psychosis.
    Pelayo-Terán JM; Diaz FJ; Pérez-Iglesias R; Suárez-Pinilla P; Tabarés-Seisdedos R; de León J; Crespo-Facorro B
    Psychol Med; 2014 Jan; 44(1):37-50. PubMed ID: 23461899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine versus haloperidol treatment in first-episode psychosis.
    Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
    Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurological soft signs in first-episode schizophrenia: State- and trait-related relationships to psychopathology, cognition and antipsychotic medication effects.
    Emsley R; Chiliza B; Asmal L; Kilian S; Riaan Olivier M; Phahladira L; Ojagbemi A; Scheffler F; Carr J; Kidd M; Dazzan P
    Schizophr Res; 2017 Oct; 188():144-150. PubMed ID: 28130002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Minor neurological and physical anomalies in patients with first-episode psychosis].
    Mhalla A; Boussaïd N; Gassab L; Gaha L; Mechri A
    Encephale; 2013 Jun; 39(3):149-54. PubMed ID: 23095597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study.
    Smith RC; Chua JW; Lipetsker B; Bhattacharyya A
    J Clin Psychiatry; 1996 Oct; 57(10):460-6. PubMed ID: 8909332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.